In this issue:
Consolidation durvalumab may be a new standard for LS-SCLC
Amivantamab–lazertinib bests osimertinib in EGFR mutated NSCLC
Liposomal irinotecan promising for relapsed SCLC
Adebrelimab-chemo followed by thoracic radiotherapy for ES-SCLC
Lymph node involvement after CRT linked to worse rectal cancer outcomes
Perioperative chemoimmunotherapy strategy viable for stage 3A NSCLC
Capmatinib is an efficacious therapy for METex14 NSCLC
ICI–induced cardiotoxicity rare but can be fatal
PFS benefit to tislelizumab-chemo combo in unresectable NSCLC
Amivantimab tolerability improved with subcutaneous formulation
Please login below to download this issue (PDF)